Literature DB >> 15163811

Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations.

Amita Shukla-Dave1, Hedvig Hricak, Steven C Eberhardt, Semra Olgac, Manickam Muruganandham, Peter T Scardino, Victor E Reuter, Jason A Koutcher, Kristen L Zakian.   

Abstract

PURPOSE: To determine whether chronic prostatitis affects three-dimensional proton magnetic resonance (MR) spectroscopic imaging in evaluation of disease in the peripheral zone.
MATERIALS AND METHODS: Combined MR imaging and three-dimensional MR spectroscopic imaging data were examined retrospectively in 12 patients with radical prostatectomy specimens that contained regions of chronic prostatitis larger than 6 mm in the peripheral zone. The 6-mm restriction was based on MR spectroscopic imaging spatial resolution of 6.25 mm. Transverse T2-weighted MR images were reviewed for changes in signal intensity (SI): normal, suspicious for cancer (nodular focal low SI), or indeterminate (focal low SI that was not nodular or contour deforming or diffuse low SI). At MR spectroscopic imaging, proton spectra were considered suspicious for cancer if the ratio of choline plus creatine to citrate was more than 2 SDs above normal mean peripheral zone values.
RESULTS: In the 12 patients, mean pretreatment prostate-specific antigen level was 5.77 +/- 2.07 (SD), and median biopsy Gleason score for the gland was 6. At MR imaging in the area of histopathologically confirmed chronic prostatitis, seven of 12 patients had focal low SI that was not nodular (contour deforming) over a region in and around the pathologically defined focus of chronic prostatitis. MR imaging in one patient showed diffuse low SI that correlated with a diffuse area of chronic prostatitis at pathologic examination. MR imaging in another patient showed nodular focal low SI that was suspicious for cancer and corresponded to a focus of chronic prostatitis at pathologic examination. The remaining three patients had no MR imaging abnormality in the region of chronic prostatitis. In the pathologically identified regions of chronic prostatitis, MR spectroscopic imaging data in nine of 12 patients demonstrated elevated choline peak and reduced or no citrate, findings that mimic those of cancer. In two patients, the spectra were normal, and in the remaining patient, the spectra were nondiagnostic.
CONCLUSION: At MR spectroscopic imaging, pathologically confirmed chronic prostatitis may demonstrate metabolic abnormality that leads to false-positive diagnosis of cancer. The most common MR imaging finding in chronic prostatitis was focal low SI that was not specific for cancer. In one patient, the MR imaging diagnosis of cancer could not be excluded. Copyright RSNA, 2004

Entities:  

Mesh:

Year:  2004        PMID: 15163811     DOI: 10.1148/radiol.2313031391

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  35 in total

1.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Oguz Akin; Changhong Yu; Kristen L Zakian; Kazuma Udo; Peter T Scardino; James Eastham; Michael W Kattan
Journal:  BJU Int       Date:  2011-09-20       Impact factor: 5.588

2.  Determination of the cutoff level of apparent diffusion coefficient values for detection of prostate cancer.

Authors:  Masako Nagayama; Yuji Watanabe; Akito Terai; Tohru Araki; Kenji Notohara; Akira Okumura; Yoshiki Amoh; Takayoshi Ishimori; Satoru Nakashita; Yoshihiro Dodo
Journal:  Jpn J Radiol       Date:  2011-09-01       Impact factor: 2.374

3.  Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Authors:  Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-02-10       Impact factor: 11.105

Review 4.  Advancements in MR imaging of the prostate: from diagnosis to interventions.

Authors:  David Bonekamp; Michael A Jacobs; Riham El-Khouli; Dan Stoianovici; Katarzyna J Macura
Journal:  Radiographics       Date:  2011 May-Jun       Impact factor: 5.333

5.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

Review 6.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12

Review 7.  Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

Authors:  John V Hegde; Robert V Mulkern; Lawrence P Panych; Fiona M Fennessy; Andriy Fedorov; Stephan E Maier; Clare M C Tempany
Journal:  J Magn Reson Imaging       Date:  2013-05       Impact factor: 4.813

8.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy.

Authors:  Alexandre Ben Cheikh; Nicolas Girouin; Marc Colombel; Jean-Marie Maréchal; Albert Gelet; Alvine Bissery; Muriel Rabilloud; Denis Lyonnet; Olivier Rouvière
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

9.  Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Nicole Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo
Journal:  Clin Cancer Res       Date:  2009-05-12       Impact factor: 12.531

Review 10.  Prostatitis: updates on diagnostic evaluation.

Authors:  Jason R Rothman; William I Jaffe
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.